<SUBMISSION>
<ACCESSION-NUMBER>0000950133-07-000914
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20070226
<ITEMS>1.01
<ITEMS>9.01
<FILING-DATE>20070302
<DATE-OF-FILING-DATE-CHANGE>20070302
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>NOVAVAX INC
<CIK>0001000694
<ASSIGNED-SIC>2836
<IRS-NUMBER>222816046
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26770
<FILM-NUMBER>07667099
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
<PHONE>4849131200
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>508 LAPP ROAD
<CITY>MALVERN
<STATE>PA
<ZIP>19355
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>w31335e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE<BR>
SECURITIES EXCHANGE ACT OF 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) February&nbsp;26, 2007</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><FONT style="border-bottom: 1px solid #000000"><B>NOVAVAX, INC.</B></FONT>
</DIV>

<DIV align="center" style="font-size: 10pt"><DIV style="margin-top: 1px"><B>(Exact name of Registrant as specified in its charter)</B></DIV></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26770</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>22-2816046</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" nowrap><B>(State or other jurisdiction
of incorporation or</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(I.R.S. Employer Identification No.)</B></TD>
</TR>


<TR valign="bottom">
    <TD align="center" valign="top"><B>organization)</B></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>


<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" colspan="2"><B>9920 Belward Campus Drive <BR>
Rockville, Maryland<BR>
(Address of principal executive offices)</B>
</TD>
    <TD>&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>20850<BR>
(Zip Code)</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top" colspan="2" nowrap><B>Registrant&#146;s telephone number, including area code:</B>
</TD>
    <TD>&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(240)&nbsp;268-2000</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>508 Lapp Road, Malvern, Pennsylvania 19355</B></DIV>

<DIV align="center" style="font-size: 10pt"><B>(Former name or former address, if changed since last report.)</B></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant<BR>
under any of the following provisions (see General Instruction A.2. below):</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> <B>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</B>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;1.01. Entry into a Material Definitive Agreement.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On March&nbsp;2, 2007, Novavax, Inc. (the &#147;Company&#148;) announced that it had entered into a worldwide
agreement to exclusively license a new virus-like particle (&#147;VLP&#148;) technology from the University
of Massachusetts Medical School. Under the agreement, the Company has the right to use this
technology to develop VLP vaccines for the prevention of any viral diseases in humans. This
technology will complement the approach that the Company has been using to create its VLP vaccines
for pandemic and seasonal influenza.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company intends to file a copy of the agreement with its Anuual Report on Form 10-K for the
year ended December&nbsp;31, 2006. A copy of the release is furnished with this report as Exhibit&nbsp;99.1.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01. Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD>(d) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Exhibits</B>
</DIV>



<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"></TD>
    <TD>&nbsp;</TD>
    <TD>99.1 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press release issued by Novavax, Inc., dated March&nbsp;2, 2007</TD>
</TR>
</TABLE>
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">Novavax, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" valign="top" align="left">(Registrant)</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">March&nbsp;2, 2007
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">By:
</TD>

    <TD align="left" valign="top" colspan="2">/s/ Jeffrey W. Church
<DIV style="font-size: 1pt; border-top: 0px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Name:
</TD>

    <TD align="left" valign="top" colspan="2">Jeffrey W. Church</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Title:
</TD>

    <TD align="left" valign="top" colspan="2">Vice President, Treasurer and Chief<BR>
Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>w31335exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="w31335w3133500.gif" alt="(NOVAVAX LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>NOVAVAX LICENSES NEW VLP TECHNOLOGY<BR>
FROM UMASS MEDICAL SCHOOL</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">ROCKVILLE,
MD (March&nbsp;2, 2007) &#151; Novavax Inc. (Nasdaq: NVAX)
announced today that it has entered into a worldwide exclusive agreement to license a new virus-like
particle (VLP) technology from the University of Massachusetts Medical School (UMMS) in Worcester.  </DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">

This technology was developed in the laboratory of Trudy G. Morrison, Ph.D., professor of molecular genetics and
microbiology at UMMS, using paramyxoviruses as a core for building a VLP vaccine.  Parts of the virus are used
as a backbone for constructing potentially safer and more effective vaccines.  This technology will complement
the approach that Novavax has been using to create its VLP vaccines for pandemic and seasonal influenza.</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Commenting on the agreement, Dr. Morrison said,
&#147;I am extremely pleased that Novavax has decided to license our VLP technology.  Novavax has established
itself as the leader in creating complex VLP vaccines as demonstrated by their work on influenza VLP vaccines.
I am confident that Novavax will make good use of our technology and I look forward to working closely with
them in advancing the VLP vaccine science.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Under terms of the agreement, Novavax will have the right to use the UMMS technology to develop VLP vaccines
for the prevention of any viral diseases in humans.  Novavax will make an upfront cash payment to UMMS.
In addition, the company will make certain payments based on development milestones as well as future royalties
on any sales of products that may be developed using the technology.
</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
&#147;This agreement substantially expands our ability to create VLP vaccines for a much broader array of viral
disease targets,&#148; said Novavax President and Chief Executive Officer Dr. Rahul Singhvi.  &#147;We have already
created VLP vaccines for a number of diseases, including both seasonal and pandemic influenza, using our current
technology based on the influenza M1 protein.  We now have this additional tool available to our scientists to
construct other VLP vaccines.&#148; </DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
Virus-like particles mimic a natural virus but do not contain a virus&#146;s genetic material required
for replication or infection. When inoculated into the body, these particles have the ability to
trigger strong immune responses that are capable of protecting
against viral infection. VLP vaccine technology, coupled with
Novavax&#146;s disposable manufacturing system, may provide a unique solution to the prevention of many viral diseases.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Novavax</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Novavax Inc. (NASDAQ: NVAX) is committed to leading the
global fight against infectious disease by creating novel, highly potent vaccines that are safer
and more effective than current preventive options. Using the company&#146;s proprietary virus-like
particle (VLP)&nbsp;and Novasome<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> adjuvant technologies, Novavax is developing vaccines to
protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. Novavax&#146;s
particulate vaccines closely match disease-causing viruses while lacking the genetic material to
cause disease, which provides potential for greater immune protection at lower doses than current
vaccines. With an exclusive portable manufacturing system that allows for rapid mass-production of
vaccines, Novavax is uniquely positioned to meet global public health needs.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About the University of Massachusetts Medical School</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The University of Massachusetts Medical School, one of the fastest growing academic health centers
in the country, has built a reputation as a world-class research institution, consistently
producing noteworthy advances in clinical and basic research. UMMS attracts more than $174&nbsp;million
in research funding annually, 80&nbsp;percent of which comes from federal funding sources. Research
funding enables UMMS scientists to explore human disease from the molecular level to large-scale
clinical trials. Basic and clinical research leads to new approaches for diagnosis, treatment and
prevention of disease. Visit <U>www.umassmed.edu</U> for additional information.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Forward-Looking Statements</I>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Statements herein relating to future financial or business performance, conditions or strategies
and other financial and business matters, including expectations regarding future revenues,
operating expenses, and clinical developments are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking
statements are subject to numerous assumptions, risks and uncertainties, which change over time.
Factors that may cause actual results to differ materially from the results discussed in the
forward-looking statements or historical experience include risks and uncertainties, including the
failure by Novavax to secure and maintain relationships with collaborators; risks relating to the
early stage of Novavax&#146;s product candidates under development; uncertainties relating to clinical
trials; risks relating to the commercialization, if any, of Novavax&#146;s proposed product candidates;
dependence on the efforts of third parties; dependence on intellectual property; competition for
clinical resources and patient enrollment from drug candidates in development by other companies
with greater resources and visibility, and risks that we may lack the financial resources and
access to capital to fund our operations. Further information on the factors and risks that could
affect Novavax&#146;s business, financial conditions and results of operations, is contained in
Novavax&#146;s filings with the U.S. Securities and Exchange Commission, which are available at
http://www.sec.gov. These forward-looking statements speak only as of the date of this press
release, and Novavax assumes no duty to update forward-looking statements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">CONTACT: Mariann Caprino, &#043; 1 240 268 2029
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>w31335w3133500.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 w31335w3133500.gif
M1TE&.#EA+P$N`.8``-WF[[;$UOG\^?3Z^CIEDZJ[S_WZ^?S\_(N@M_WZ_>3L
M]$=OFA9/B<;-V-;=Y1E.@Q9/AB17BN/F[5)WH.WR]_S\^A50AOGY]6:&J?/T
M]!10B1)1B?GZ_)2IPOK]_,O1X?S\_O;[]1M*?G>6O/SY]O'V^?K]_L73XA)1
MAOS\]A-/A?KZ^HJCP?S\^/GV^`Y.AOG\]AA-B1).B0]2B2I;C_OZ]_GV\Q9.
MC?CZ^AQ1A1%1C)ZPQW:7OQM3BW.1M'F5NVF+L+O*W/?\^Q5-@31>BG*-L190
M@GV4L??Z]\'/X724KEV"JO'Q\&^1LF^*J_SX\OKX^/SX^^KO\?[[^L_7XW28
MO/?]_GR:OOCY\^WK[?C^_O;W]_C^^A)2@\/5Y1!.C!)1D!!.@L_<Z?[[]^[N
M\_K^^_?X_/[[_%U]HH.>O9NSS\C5ZO[\\R]AD_O^]S]KFQ1/CQ10C"11@0]1
MCQ-+AGV9MQ9+AFA^H!9+B1)+?_O]^O[[_MG@ZPY,C150B/W]_2'Y!```````
M+``````O`2X```?_@#R"@X15(SQ!(6Q[>W\'?Y"06FP>%!V$@E5*4E&1GI$>
M)A4U44A\.TL1?7U?<U\:?A:R-S(O0P0C`0H<''H''F,5GS@-AU68AR-\'(^?
MSI!C(`<'$H>$/R,C/WS/D`)0406&F(0L+D)3S9$5("`E:>2$!2L))E,FW<Y0
M+FH_/_$%3*B+U,)#!2$4KHRHPA#3CRL.0B3PY$'+%#Y7>%3YMQ%3@0LP]IQQ
MIN?/G@JFK"'[4<6!@&<W8LJ<"4&#CC8E6H#8<T"8IP-LQBAX,_/&#`TB`'3*
M-U)/!C5O'H1!D<."'P@Q8D"(I<("A`=@40R!,&3"APMN#H!P\\D`GS8W_V(P
MF!ECQHLB%4KF^VFB!I0.1>/&)+#TF0<A9"*`B1-8)IX=-?)^`I'@#`D@7QH/
M5JK%Y]Y(5JA$Z+(!SDP&1@IHL:(W4ID_8U9TF,O8M$P&#.+X&#"`8HL4`SK,
M8?"@9HRB=CZD`.$94CM(;B@0`:.A:!P=<YP@,?`,@O?OX./(@K";%X@IGPZ4
ML3(4/(0-2`&,>79@A?TH+&B$D67$0AS<$!C1GQ\$$JC!!G[$8($&#/@APP)!
M(&'%!<T)848=7UP%W@U=6$"#"\WM!<(?'C!!`P/@66#$!F%TL$(^I#@AGGON
MW=#&%H^,&,D9;KA10Q`YT/B=##L88$)KGSF2QO\+**"`XG<63,#$+RVDY\$*
M9.10G)`6S!!#!`K`X$P*!FQ1A`8R;+"!$>`Q@`(1$B"!Q$_M""#$`$?41%R*
M*"PP@"_/R"+HH!;`L:(&/5`Q@`!GC.3)%"EX,!2AN"7UDC/3K'#"`D/\!^!6
M&H0*2X$$-LG@#6JJX$<<$.3@A`)1#`0##E3D,$-7@L*Q`0-X!!%B/GMX($``
M,L0B*`I&,-`&$Q[DTX($/9#&`*&#^O'"#E/L@4\D!W!1!A04+.$'KH1N@`84
MOVR;I!EOJ,"`7(/2L0,4P2*9KFPO>.='J-7JP(`=0(1`YQD<#"#%!`>Z.:@*
M7<B`!@4O<LLC#`,48`?_!!:`02@$;TCP"Y*1B"JRJ%^AX,<-$Y20PC2?0'K`
M4".#E=1`?U1000(X%-"&!0PPN(&_,1@1*L8SH-"5L1#$P2`**M:$L0P3`$!"
M#0GT-(802*#QPL@6;*""!DO`((!:+'=CP&$^R+"@J%X-X8,`''C"CA8'$'PF
M"O"AH(/0\+$]0QL9Q/J)"6Z0($`!6UN`M\@S@-D3R)_H<48"`G@!09,/J,FO
M''&"H$6SW!Z`@P(GAJIFWFON"U\/"AA`M0DIG`&"G2'P08-W*(R\@50[(+%"
M.E-XT,(8.#A`P`O3;J"BFF\&$-D9-$-"ZO34&^'\%"'>8\)0TZ.85(@51!%.
M_PY&D%I3'#'XT;/1Q:'YPND,P*&!505:\,"X1/!Q@14K!^]!`U\H5H&VDB8Y
M4``&!MB#-/(QA14XH`TRV$J!;F"!"#1@!4+XR1],8(`5`$`$25/?#&Y0/I,-
M4`,OF$?T(D&!"&@``@Q`4(%0D`<6Z&$*D/.$&\X0A1`L008R"!4<IE4+!%0@
M8NF)`@XZ,(2>B>Q02A./!<+P@QH(P`!KD=L`DB"'%ZBJ0`SJ`@3D$`0#&.``
M*="#ZUR`AOO5KR8JZ($*5R@]ZMG103W(0@5HICWND<I[`,B>`:@@AU>02@-@
MV!MQ'A"'.<0A`C2@002D(H,XW&]4!,*8=^:P``D((?\!.O&`'FQ`@^G)0@<J
M2"$X#I##2"1`-C)`$:F^,`,@N*`&H(,$/J9``B@4004/T,$+EZ8X4MG/"$2@
M`!W_@`,UO.`!,3!A)E7PAC_H(9?.&%%],A`!(`I103H(`Q_J\XP67(0`?CB*
MJ/R@`XS%X3]:&8(1`("$:SH*$GH0`A34<(,&U<\"8HP!`<B`A+S4YPP(<-<A
M;Z`!%.Q``/99YAWMJ`,+U&$`4&B9";;WANY!X'N?6$$6:*`K3,8"+/YYP`0*
MX(`,@,,`+LC"!SI`A!?(XI!SF,-[9(`!+-3#<RFH00&&$`L"R6(#$-#!!,Q@
M@#+\RA,<P,$"-G`#"1)H`T/_",(4@C>X`Y#@`\CSCQ\>T(4O$4&`F<2-$7:0
M0;,I`)I"^Z/7^("$N'4#>F7@0`&"*"H4N6D"R]1#"-*`!PBH4U3M>H`1'O"N
MK,P``RO@@A:XXXDQ:`$'++`#KM2G`P0I#@U;V*,'BM>#GOW1#B@8@0VJ])F)
M4L]-$0C`!33*48^"U!-X8D`[Z4<@L&B`#A,(P`!P4(.IU>"X-<`!EM1`@R\:
MJ+,8TT`<`E"!E^C!1Q0H)?TD:+\7.``&7)A//E:PAASLRI^97$`)IJ$C2%1`
M(!D`@@X8Z94`Q:$)!0C#'UG%,0#DPZM`<*)<+?"#%5SJ&=#S0!06L#9^804"
M'S@P_Z84T`;B]"U4#^`#`31@!#&R*@9SB`$?A%"&>SHB+S6@`!".IC[%4=`"
M0U`#V:1`@-R@-Q8H>!@4D)B/Z;43-S)X0*'FAQH53&`+OO"`!P[0QX[^\:.!
M')'-*B"&'*AM0`6JZ`LP(($5A,(@OQ"6`#QP!ON<8,/\&D]TX?`&+.``>WJH
M``><@!N>;05C#WA!!X00Y\A94P]6($$18"B>GA%Q'F78B2?.(``!-,"%#WBA
MOE30`.G(0%4;4!J*'M`!9J1C(.$3@W],"A\/90";+?L-']1&J@XQ@`!FD'!>
MZ%8?!%RY01N(X`0XD`89K&A!/"O6$81@LY^<!&Y#Z8IW%/_W'\7U@`\KV$(=
MV*2#?AYH06WH\AB6&0D?EQ620M:8380\A!V0@`/OW>I&_5@@0+)#6#5801W"
M<"`L$X@!+W@#!="5I&DD@09'D26IP#`$*G``/9'@0P\8:MH"O6`"%*@9-O40
MYWRZX';O`79%<T`&#I!Y(`G@0`V6@"92N6L"RMUK$+LFLAOA(`&-^`D&%U"3
M0[YP"!]`]4\.X(8.L+I^*OA"!PS`!;E=\P`<((,<<L<S-[U+#&XA@A'B<,@X
MB$`,*Z"L8200`>59-19&B,$;F!``$11'35U@$`0BL`9ZL25)TSM0#-I0``OH
MH)UQF,$#OA8!"EP@&AYHLFT#^0C_X@*``)=NY]?MT`-Z4N@STS@`%';P@K+>
M.&DJN,,*3.S#&/*,5`_(01`.4!!/F*`%[QU#$&ZUH#CL;@XR.,(3!'">@:0@
M"A\8@IK^*(,DV*>%TVIPJ(:```Y`3UTD@IO%>&LL?!=!PI^X4@::RWP8ML$%
M!I"PDL.W`EO7!*GO8<`"K,"+-!@!K?NJ11V>0(+_0B$(/9!A_<)@6`P08`A"
M[IGB9B!'&^#@`,C78W^$*D1@!@LP-#\#0S.@`TOP!`!8!H+W9-\#/5:P`@6@
M/'[@=:"'`5-0!BGP5,^0`B82?N:C`7.0`^OE"2L0`$+&(.:S`56P`O]G>A70
M0%"P`(ED_P$,-5:^I@!LX`;V\`D"D`!3]3-_1`!OI@<"8&O],3(00`,ET"SM
M!0ED9@8$X$9&U2`SP``*L`(K)``X$`#O4WTQ4`=Z,`:HME%0D`4]T$YW!U`6
M8`=!D$%[X``B<&,,H#$T\`'+5#=3L`,88TQ=H#2E@1L;$`,,`D0=``.`Q@8(
MUUI_5!=M,`!5AE2K,G7*TWLDH`7FM&Y.UFY05@&-4H%I\!7*<U,%D@->(%I)
M$@DI@`4L@"K5EVDO0`4#42(3@#=XN`$$4`)>Z`Q38``?Q`"Q!`N[8P%HP&<I
M8!%3.`5)P#1B52`J$"%G4`$&H`"3M"HB8P$O8$.LM7,<L`/.%?\+FO8%!4!.
MSE`!%U`$U&%2%?0!V#.%OP`"4,`"7\`F><,T"V`&:6$"..`$Z-<S>P<$W&8/
M)<`"1`6*##`#79`;0P,!$:0$&7`!9:`%.]2*'F4!;8`#6%`$R%(30H,B<+``
M3-!H$0B*WU,U'K`%2_`5+\1\?D`$)2`$2\9MGA!O25",'O4",N8),#!Y*K`K
MI'(#*!`#`8`$-.,+*Z`&;((;*&!8`1(`'E<!95`W!T!K6[``,O"4^L<@!+`%
M."`-%8`#(Z`"$&E,C\0$-0!J4P`".$`&%19^TL4S-X`!)3!F.E$STI`";U%1
MI<9A&P`$.'(`,0<)2"<`7*<!]X,@#>7_4&;P@2"P`A_P!5\3:?,C71$@`08@
M)LSQ#%B"!O`!0VKG:JBR)@_P!0M`!BO`B!4QA0)H3!#0!AP``]*!+-,3`W30
M`1?P.YXX>#?#'%)P@'$G*KO6"^G0BC53`0J0!S4'1EHA`TUPBRN@`'(0B,;$
M`&'3'-=U`"70+J1B!!6U`#B`3;+3`D*P`DEPA^)Q%4)C!SM@'^X%!0I@93I@
M/IVU`X)#$&VY`AQP!'9@=\T9"S1`!9&A!SS!#FCD<TB%-\'D!T/@//90F'\P
M!1P@`'6`A08B=JTC``9J`$BP87O3-5T#!RK@!"00`FKQB"JX`E)P5C$@9,94
M3%E!`U*0`M:$_YS=9DJQ&54"(([4HP'`1`4D<)+W%HKWX`$`0`0FM2^B`@1F
M($IETXH',``YT`/C6)1)`UB>(`1(EU!?9P&(V`-,T!Q',@4-,`3,5RAXT`$A
M@$UJ,08PD`%:J0)2]`"YTXOHZ#H7@`%W-X`,(`<*@$TUB'0<\`$1T"0P9'(L
M\!OXD",@D`$38)9NLCL+2``9\`0686*;Z0!D85(,\`5L!0-B<@;)12RTE'^(
M.$8*0)-!Z`SV40.)&6GFDW^(L@9/L(PXFJ.P*9O!DP%H,(X9&`-?L`090*3J
M$XI4:0(.0`-+*C(C$`45H'-)8@7=-#U/B0(C.3A_8``2P)RDPBH:,/\#Y[BE
M!M"?7V-,,D``GM0<TV`"3U``K[`@3/,`-Z`"'4`S-<@'.=`]U\8"=F68Q?8'
M*^`$&_"4)M4GZ.(!;`$"'&`&`5`5$&`4'&98!4`";$!KGM`"2#`"5V5,>907
MOG`&+5`&6-`&1Q$T[P*F,^`#)&`%6B!>]#$`:I`F<:<K>L<"44`">B`*N?H'
MU.,5O'H8A-0],?`".8`MO2F!@:0'7&`"HM&LHE('48!+`0AY`D`#/U<JEY.M
MGA!G!V`&:/!U_V$T;_"O`NL6:&8^*H"S_!8)P5,&63`!8!!I3<(S8@<`/'8D
M!S!R[L@T&M`&W!`)YU$E>@`#04`'"B)-XP+_`6N0`-?U!PP[9[&4-+FS6!%`
M!L#`!30#`R=``T(F?^.R9XWR!V>P!RG`!23@<SI(;0DR!P\@`7I0E?^E``0@
MFG^T/K?`!Y&A!2:&D3K*JW)F!D>`5`S"(%WC!P0PIAS`;D7Z/9I[`,M*=3^J
M`3]``C"@9#89.@(0`5MS2$T2!PL`:G)6J$VT(#4Q/W3P``#0`G7C(Q>P`RQG
M<@\@!AQP1G(S9CL@D`W5-?["`D@0ENT``B9`-R10`#W`5XK#,W%@!VG`9SPQ
M#<*@A!GP!C'0!8IK`3+@`UX8#%<"ET,S/R;S`$?@9:RD%IYS``*`!#[`7VMS
MB#D```,`<R`@.]%Z_P`CI0'19'=`Y@<(T&BH5A('$`5,L`1AH!4+TB#ZYQ4,
M8&1;X&43D:L_NZ-NL$=FD!@XK#1&90$JH`0D$`7,>ZS.>Q(`T`:NA0$"$`)Z
MBYQU4P)R<*X3A`)=H`)H`&J0V["(IXL-<E-JP`8&<`8I(">@Z8+2>`<UD!8#
M@48#$!5?YQTQ(`$U``-E$,EEH&1C0`(E,`%-A#Y.%"HT`#'5^!K<4@$%,`=!
M:4P:0`/Q=@93T`(K`(@O:#^!NF@@P`6K"0!R(%W3LB=?``0^+,F2S`47D#;'
MZYR64@-=VQ,K,``LD!7G6[RX87(J4`4DT$$]&\6R:3.$&@!%_,Q<80'/5O\#
M4O")S1M(7,`3%#`!7S<]*&<%V>L)S`$`=&"=]\8T$'`%(*,6O+`#=.!J>:P"
M*D``-A"MD`(`.5"4-T8')U#(4?H'+>`"'4!_XXC!./L$8\`(C)``T@`"`Q``
M>5`LPT0R/F`&+>`&H.P-<5I:)L4F7_`!-`D,'$!SYB,_:!`"11<)%#<*!K`$
M9@E=EA1$$A`%"0!S%LT('H`%ADH:"Z4!:4`",.L(2W8!!?!@IM4SYS4]*F`'
M%0M]</>[9OL'2(#.\DP@<_`&6_#%[K9#4^H$Z4PJ$5`",9RK.!,`%/1UN1P#
M!=`<C=(,-M`&3*,@I/("#<`!94`Y//`"7M+/,8G_!#4``DOF"090`C00OP4"
M1$O@`TUPV9B=V4W@!`]0+"@B,FM'`64@-A11$G40SZ"7@4N``U80>`"0D`,D
M`W;0``+0''GAKA(`!FO262FE`S2@!)H=W#[0!O3Z1_Y"`PY0&*0;!4(0!!&`
M&\]<7Q<SCN^R`6"0!&("Q5SM7C:S!0X0`14U/5^`!P5@UJ'H!E/`:!U@!Q,5
M`VH``Q/1SG^0`$@`!'#@%=,3=C$``$C""-`C6&GP+M/2:D7@<6?@`FU0L.IC
M+!90`"$`U&_G2AVP;)ZJ`T\9`VHC*&:Y=S&@`D-02:(I*D93!V,S$"9P!GHP
MGU^7/E01J`>0`*4(ND;0_R=1L`)XW2PDL`3SQ7*Y(V0W,`3^'.0+XQT-=0/&
M_0!#,`)/;)A0\!81U#?3$@9V0`-#H+C>T4AO(`;5O-W<S0$D\`,82"J[0@1B
M(,Y@'$A[5!]!<,LR8,$FI0%'%@5C4!FE&SU:$#L\I'`!FDG^`87VPA.0(`0?
M0`,Y;$R`VA-K<#$@^1]/>)<P=UV4\1MD0%)(I<30/0<4E!LS$2H]`P=PD":=
M=;`,T`-=IJ+2(%B@F31>`2]A$`"BN@6$/HYCT6D]\1,&P0=++&16X22A(@/'
MH1GSHP)-\LRA<JP;0`-9T!.:FP*02@>KPK_WHP(1$`1MT)#1-2V7(\<EX+@F
M(/^MGV#-7;VW$N"=0YEV0&#F[F:8*\`$$Y`F\Y.F1A`$)$`"::2PC0T:"J0'
M6E`"(P`&8G1Y<?`%1\`,^9#"11#>WSH$!6``0K`$<J%62B,#14#'./.^1O`%
MX(<;TL4@T-WQ'C\M'2(H?P0'#X``:^G.(^MHQ3)?/FX3$Z#8#1!!S/?/$J`%
MK0H)4P!10/#AKO7Q/M_Q:?9.L2<`?\R10,!8R<).J+$!,Q``XZ.#17-C;H,%
M>>&:SP#NZ5$!,!``[#V44Y<^OJGNK2P#.M!LQO0`C;<"`KP:;H`DGU,/!Y"_
M**!W-_8SC7SRW=!+08`\I!8'&&`#4A`DSUP^&Y"9V)3_`**$`[8<)$=L.GAS
M.I`?^6HB*-!M3$$S,YZP!U.@!5!@``LP`UXBJUZ1!\GM!$>EJ%#0M"IJO51`
M!VYL()(?^Y+/\4F,/E_0`U(P-1>@!I*Z]'&``@\P`]K!`?B!(C-PB-]JCFS`
M9%N]JUW]!VX@`&9P!_Z\7?YQ'6'O"5)PRY5?($@5`S3@!0)P`4_`!G@/"2O`
M!D]P`1W0`U@Q`ZA(("J@`W=`(7TX!0/`*>+M!Q$`""<%#(0:&C<6,1A(?XV-
M!B9"%U=S,19^&H1^*ETJGI^@H9XR##<,?JA^$"@:%E="!P>-!V=:*5$[$"\Q
M$'$H$!!^'0`/&Q!PJ"H6(@XU_P<F((Y_*P--F1NI?A:BW-P]$(2E.AL6<VE/
M)`$/,48,<"@6&P\/"Q1/'E8E$S)&7:>I%E#T^+!"@+2#CK*AL@"A#8>#!UIX
MP,&GAX5+?ABPLJ20`001`"H<%%``Q0-#V0S%>!%!B1@;*81XD+:"0I`E,C;$
MN-$ESK^%-/A$D8G0D8DS;@+8"9:*EXHT"S(9VA`GCIP`%V0YFN*!BX,8.C3Z
MA'`CQKRS:-.J!<9T(0H=1FA0B>5HCPD#*R2\D<%0ATD_,B9T4&$R3BH50$*L
M2.#!A#0A02*<1)$-0@ZUF-7&B$$(G*$'.GI(2-*&\X,X&B!<'$(D"0X#!CS`
M`$#CAO\1R@"-Q&DC1DC1@PJU-7QX\(R'%372#&'0*HX%#;PZ?@QY<$6&"4-0
MC].@0RJ##3-H8.@0X(,#*DD*I)G08P8KU18,0\@$P0@+#E$$S/QM0H\`)A$D
MHD$[P%C0A@J%&,+`%Q,P`<-^LW`P0!W&&!('!#UI,$$`'';HX8<?HB$"`_&<
M@H)S#RC!`10'Z/&'+&<(L`(+='1AA`X6&*'!!A&T0<X#K+021A(RGO$'""!H
MT2(.0'QA1#P#>F)$&B!6"2*-$(#%$`,GR<#"/C=L<(,&?H`&01@=0*'?`2!4
M@$0!#ZRR8SC@S+"$`AQPD,`?$$H3'$,._=9("42H1F9PJ7C_!))(TD1A@!1$
M?%'F`\PIM!D$0^2AZ0M]]"&#(2AE8X$.F.)11`D<:"7H'FYXD)P,$.APTD_!
M/2"#&GKD*HT``IP0@0PJ9&-,'U@Q*J@T>NR!1!(1Q#"#!6$N9$$$$D0!P@%]
M5L"'"+?1JE`7.ZI`A!G23'%`&2L((48.5*GFG`H01*``"5.4T>>Q%91``UDZ
M9,.`"IQQ!JH&_'R!1@E12#/1"DX$6V)GW]FA!,)<18/0G\,=BT0`\&*#*"J*
M4B=-#36$($&A63+PI$*M;!-&%R\P(#"H'?GU`@89K,"!'B:HBE`"K9(@17NR
M/O=Q1G)(\8<6!XU1`Q`TIZ+#"PNX_W"!D<<ZHD<%>X2PA1,QS$&IQPLYP<$>
M!QC[1PA(%#&JMY7%$T8!?4XQQ1A(X+#/J!=EX@<>+-200`5N6)SUBQQ4H<P#
ME2'HT7P#;T"$`F:LH'`-`FRQ`*P6A%.,!BBH@``)>B2P1U$8!RIH#3!@4-_1
M&4VG-I]<'"`$'Q,\,(-[APJ[P0:]HS*P0L:(4$<)`FAQQAAT_6:`DB1$<<<&
M,C`>O$(J=(!$X0<A(48/O].*@@Q!N%&!S\<6SFH%#;P@0PRM5!9'2"OX#,,*
M5.S85G`,^$-#!G5CWA,<,`=C;``>T!$($\;0I@HXYG`OPH$"(F"$&*2$.:=@
M#LV&0(44Z/\!?2TX0`VH0(0AY$`%.]+!#%06F@`@H0*S:T3JB/,;&`A``40P
M`NQ"-CO&<(%U9&"!9,`A*G"4@A`7><[PM'&1![RA`"3`0?(J<(8SH*]<2IJ"
M`#Z0@]1@XF@/D(`06F`N:>A-3"3*A@H(X`(N<`V"?W!#?_3@@0N@X0NGZ$+C
MG("Y;"7`!6_XQ=&><X,CA,!GQO&`#28@MHMH@T0H:`()SA4+ID%0BQSP`0HO
MN('O:%`E+,!!B]R`K,*1X$V74<;OL&$$",B`!LVH05%"(0,4@*$-+CB6?B[`
M@AAT8Q0R`$D*#C(%XSQ(`"3X``8B\(74`&,S`3.$,K:A@3C(X%/_X!E"&U@`
M`&><[P\?O):@L&5%`2P2#L"BY3490`<T<$"4WXS%`<1@!("!XB(J*(`+//!!
M.#;B@R9H01`8\+Y0T&$(1@``#JP@C0,D(`H%@-<O51"'"```%M(X`Q?T0`4[
MJ.`!H(#`#'+`!P&8H`RQN-<X#[`"9GU!%*$;!2&^L`!4[4$/+3B(BP0PA1+X
M($[PZ!M#XK&`+`C!16C;#S0W\P`1L&8+6>N/%":PU*JRPP@@,<"QM*`D#O"A
M#@2(DP6^`(>R;`)8A#`%.&(0AAPL8`<Y:YX_#\*&'8C@`15<*C"&,(0'B&$%
MEG,$2[<P`1%LY@MEB0$>\-"&`=3@=*2<_VLC/$"H>60)FGB%P!&@H%5':*$"
M8Q@`$:RZ5!D,`0-C.,/I'`&"*#P!)S*SJA-<D##)\JD,;!@`$/!`6LRJ(`P1
MX(,\LW8`"A#A4QA92#%BX(02N.$`YMK/!Z8[72]\X`0G@`*^^C,`!5#WN]3%
M[@E*T-G?I"`%;I!1%,P@@0)@@`!RR,,+OD#?^O8A!A%80!V28`\2I$JNMOT#
M#*1P`B^<`+S7I:XH?3;8!DQ7O-_E`Q($@#87V;8"LX%P>+VPAA-D0):.@.':
MQ'!@!(=7`FPZR$0R\($D@+?`7I!""$!\83T(`0`E-O$'O&!@/CBC?L3=`@!Z
MP)G*3,8('5C:&/]28+B,F@Y)Z6.5&Z9P+"1)Y(K2V,,>$F"Z,3#O#W>S`1DD
MX(`/-*`!5'"`!&1,QP14D4\!1@@(SC`%$Y21M4A"$I8GZX$^^]G/-2A#LO9\
MN`J`8'`5L/!DS\"&,FAA##IE<@7*("A^3B$!4QBF(\Z0@HVV(+*SP.T9K!!#
M".8J%HD>IYOM]D!3'Z``RQ&5$<!PD0@4``=NU(H\8P$"*I_T6&4X@Q[<\,%=
M&YL+'DB!%A1=%-6JJL]\BL4*6D"",9#@VB2PH0!:=#YH`#C.PBZ#%:ZUZ_U4
MX,Y%T;-#&6R%%.P!:Q?N65>*G=*`>D`+.36*!RX]!BL8N]S0]4`+F-W_HMJE
MP`/_YHH)(!U@#QC`S4KZMSP;HP<V6/)P;)H"%(`P!);M2$=R,0B6(W(D0D?[
M`%9@-D+8X&5^%EH/E!8QGQ".K3[K9]O0K:*(08"V.#<T5QY(0)--T.ICL0E)
M0I>&"?`]YSA/6@_74AN;#)#B@^@Y!45'2`7N#6!4T[GHM)BT+0+,)BW3<9QG
MZ,\85"HH0WMU`=;,""$VT`5PR&`!3/AFDWW.][[[_>^`#[S@!T]XGQ,.!!,Y
M00YR``>?B$H#*L"`#0RPA[T7_O*8S[SF-\_YSHM$9S@H0!B<8YA$[>@+':`7
MVSO/^M:[_O6P)WS8&]$"&]PA#"J001%/)(,`3'@M]L`/OO"'3_P7G2&$?TC!
M"J1``'B)*CZP:D,22%#\ZEO_^MB/<]AE40$."*$!WQ`5-F`5@P4H+?OH3[_Z
0U\^U%70`;JF0P0TF$`@`.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
